VivoSeq
Other

NHL

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

NHL is an early-stage landscape with 0 programs across 2 companies. The most active players are MEI Pharma, Inc., Gilead.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

MEI Pharma, Inc.

0 programs

PreclinicalGilead logo

Gilead

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed3 · 43%
Unknown status2 · 29%
Not yet recruiting1 · 14%
Terminated1 · 14%

Clinical Trials

Trial Activity

7 trials

Obinutuzumab in Chinese Real-world Patients With iNHL
Not yet recruiting·—·N/A·NCT05968001·400 enrolled
Allo-hNHL (FluBuCy)
Completed·IInstitut fuer anwendungsorientierte Forschung und klinische Studien GmbH·Phase 2·NCT00785330·84 enrolled
NHLBI Type II Coronary Intervention Study
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000594
Safety Study of NHL With 90Y-hLL2 IgG
Completed·Gilead logoGilead·Phase 1/2·NCT00421395·59 enrolled
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Terminated·MMEI Pharma, Inc.·Phase 3·NCT04745832·82 enrolled
Freiburg ZNS-NHL Study
Unknown status·UUniversity Hospital Freiburg·Phase 2·NCT00647049·78 enrolled
Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease
Unknown status·—·Phase 1·NCT00515892·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)